Does it matter? Discounting and its role in the cost-effectiveness of preventative interventions. The case of HPV vaccination  by Starkie Camejo, H. et al.
ww.sciencedirect.com
p u b l i c h e a l t h 1 2 9 ( 2 0 1 5 ) 9 8 9e9 9 2Available online at wPublic Health
journal homepage: www.elsevier .com/puheShort CommunicationDoes it matter? Discounting and its role in the
cost-effectiveness of preventative interventions.
The case of HPV vaccination*H. Starkie Camejo a,*, X. Li b, G. Van Kriekinge b
a GSK Vaccines, London, United Kingdom
b GSK Vaccines, Wavre, Belgiuma r t i c l e i n f o
Article history:
Received 13 June 2014
Received in revised form
20 February 2015
Accepted 20 February 2015
Available online 31 March 2015Abbreviations: bHPV, AS04-adjuvanted HP
warts; HPV, human papillomavirus; NICE, N
HPV-6/11/16/18 vaccine.
* Previous congress activities: These data h
November 2013.
* Corresponding author. GSK Vaccines, Stock
þ44 208 9902931.
E-mail address: helen.j.starkie-camejo@g
http://dx.doi.org/10.1016/j.puhe.2015.02.028
0033-3506/© 2015 GlaxoSmithKline Biologica
cense (http://creativecommons.org/licenses/the profiles of bHPV and qHPV differ markedly, which has
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Human papillomavirus (HPV) infection is the necessary cause
of cervical cancer (CC), which is the fourth most common
cancer in women worldwide in 2012.1 In the United Kingdom
(UK), a HPV vaccination programme is delivered to girls aged
12e13 years, the primary aim of which is to prevent CC. Sec-
ondary aims include prevention of other cancers (including
vulvar and vaginal) and protection against genital warts (GW).
Two prophylactic HPV vaccines are currently available:
AS04-adjuvanted HPV-16/18 vaccine (bHPV) (Cervarix™, GSK,
Belgium) andHPV-6/11/16/18 vaccine (qHPV) (Gardasil™, Merck
and Co., Inc., USA). However, unlike some vaccines which can
be considered to be interchangeable (e.g. trivalent flu vaccine),V-16/18 vaccine; CC, cer
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In the UK, the HPV vaccination programme started in 2008
using the bHPV. In 2011, the UK government changed the
criteria for the tender renewal, which led to GSK not submit-
ting for the tender. Consequently, qHPVwas introduced in the
UK HPV vaccination programme from 2012 onwards. A new
providing a further opportunity to assess both vaccines.
Like many public health programmes, the expected bene-
fits of the HPV vaccination programme are predicted to be long
lasting: CC can occur at any age in a woman's life, and it is
anticipated that the protective benefits of vaccination
continue throughout.
TheNational Institute forHealthandCareExcellence (NICE)
has recognized that for interventions, such as vaccination
againstCC,wherewith costs occur at the onset of a programme
and effects are seen only after many years, cost-effectiveness
analyses are very sensitive to the discount rate used.3 Both the
updated guidelines for the appraisal of Public Health and for
technology appraisal (April 2013) fromNICE suggest applying a
discount rate of 1.5% (instead of 3.5%) for costs and outcomes
when long-term health benefits are likely to be achieved.3,4
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Table 1 e Model main input data and outcomes.
Input data
Vaccine efficacy cross-protectiona,2
bHPV qHPV
CIN1 47.7% 23.0%
CIN2/3 68.4% 33.0%
p u b l i c h e a l t h 1 2 9 ( 2 0 1 5 ) 9 8 9e9 9 2990rate when assessing the comparative costs and benefits of the
HPV vaccination programme in the UK. In this analysis, the
impact of time was estimated on the valuation (costs and
benefits) of preventing different outcomes associated with
HPV vaccination with bHPV and qHPV, before considering the
impact on the cost-effectiveness of HPV vaccination in the UK
when applying a discount rate of 1.5%, rather than 3.5%.
CC 68.4% 33.0%
GW 34.5%b N/A
Disutilities2
CIN1 0.013
CIN2/3 0.013
CC 0.273
GW 0.018
Outcomes
bHPV qHPV Difference
(bHPV e qHPV)
Disease impact results (undiscounted)
Life-years gained 6,947,058 6,946,644 414
Remaining CC cases 125 179 54
Remaining CC deaths 55 78 23
Detected CIN2/3 cases 5025 6485 1460
Detected CIN1 cases 5955 6231 276
GW cases
No cross-protection
against HPV-6/11
for bHPV
10,828 3027 7801
Cross-protection
against HPV-6/11
for bHPV
8276 3027 5249
Cost-effectiveness results (at 3.5% discount rate)
Total cost £35,525,409 £36,612,903 £-1,087,494
Total QALYs 2,653,529 2,653,581 52
Cross-protection against HPV-6/11 for bHPV
Total cost £35,237,255 £36,612,903 £-1,375,648
Total QALY 2,653,576 2,653,581 5
Cost-effectiveness results (at 1.5% discount rate)
Total cost £48,547,960 £50,924,737 £-2,376,777
Total QALYs 4,316,199 4,316,146 53
Cross-protection against HPV-6/11 for bHPV
Total cost £48,177,491 £50,924,737 £-2,747,246
Total QALY 4,316,260 4,316,146 114
Impact of time
% of total undiscounted
QALYs gained
After 30 years After lifetime
At 1.5% At 3.5% At 1.5% At 3.5%
GW-related 76% 59% 80% 62%
CC-related 5% 3% 60% 24%
bHPV: HPV-16/18 vaccine; CC: cervical cancer; CIN: cervical intra-
epithelial neoplasia; HPV: human papillomavirus; GW: genital
warts; QALYs: quality-adjusted life years; qHPV: HPV-6/11/16/18
vaccine.
a Cross-protection against HPV-31/33/35/39/45/51/52/56/58/59.
b Sensitivity analysis.Model structure and input data
A previously published lifetime Markov model was adapted,
replicating the natural history of high- and low-risk HPV
infection, alongside routine screening, for the UK and the
modelwas run for a cohort of girls aged 12 years (N¼ 100,000).2
Input parameters and assumptions were retrieved from
the literature, public databases and expert opinion. Clinically,
the protection offered by the 3- and 2-dose bHPV schedules
against HPV-16 andHPV-18was assumed to be identical based
on clinical trial results and set at 98% for both vaccines.5
Reported differences between the vaccines on cross-
protection were applied for the ten most prevalent HPV
types (i.e. HPV-31/33/35/39/45/51/52/56/58/59, see Table 1 for
details).2 The quality of life detriment for each endpoint used
in themodel is reported in Table 1. A lifelong duration and a 2-
dose vaccination schedulewere assumed for each vaccine and
the same price per dose at £80.50.
Expected outcomes of the HPV vaccination programme
using bHPV and qHPV were estimated assuming vaccination
of 100,000 girls. Costs and QALYs were evaluated with and
without discounting (1.5 and 3.5%) over lifetime and over time.
The incremental cost-effectiveness ratio was evaluated at a
discount rate of 1.5% for both costs and outcomes, and con-
trasted with rates of 3.5% to assess the impact of the discount
rate, and hence time, on the results. Additionally, the authors
looked at the impact of time and determined the proportion of
total QALYs gained (vaccinated with qHPV vs. unvaccinated
population) that could be achieved for CC and genital warts
separately, after lifetime or 30 years at 3.5% and 1.5%
compared with 0% discount rate.
Scenario analyses were carried out with inclusion of effi-
cacy against GW caused by HPV-6/11 for the bHPV with a
34.5% efficacy against 6-month persistent infection, as per
recently published clinical trial evidence and recent data
observed in the UK.6
A sensitivity analysis assessed the effect on the results of
including a limited duration of protection for both vaccines
and a discount rate of 1.5%: a duration of protection of 50 years
was assumed for bHPV based on reported modelling of
vaccine-generated antibodies, and a duration of 10 years for
HPV types 18 and 6 of the qHPVbased on loss of non-inferiority
vs. the 3-dose schedule for these types.7,8 A booster dose
covering 40% of the target population was assumed when
duration of protection lasted until below age 55.Results
The model estimated that per 100,000 girls vaccinated, using
the bHPV rather than the qHPV, was expected to save morelife-years, to avoidmore CC cases, CC deaths, screen-detected
CIN2/3 cases and screen-detected CIN1 cases (see Table 1 for
details).
The qHPV is expected to protect against 7801 more
cases of GW compared with the bHPV. Assuming cross-
protection against HPV-6/11 for the bHPV as observed in
a recent UK study, this difference could reduce to 5249
(Table 1).
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With a discount rate of 1.5%, the use of the bHPVwould lead to
cost savings and would generate additional quality-adjusted
life years (QALYs) when compared with the qHPV (Table 1).
Conversely, a discount rate of 3.5% would lead to cost savings
but also to less QALYs gained when compared with the qHPV.
This difference occurs as a direct result of the impact of time
on the contribution of utilities into both the benefit and cost
parts of the cost-effectiveness equation.
Assuming cross-protection of bHPV against HPV-6/11 re-
sults in 114 (5) more QALYs gained and £2.7 (£1.4) million
saved with a discount rate of 1.5% (3.5%) compared with the
assumption of no cross-protection (Table 1).
When assuming a duration of protection of 10 years only
for the qHPV and 50 years for the bHPV, £6.4 (£4.1) million
would be saved and 156 (9) more QALYs gained, with a dis-
count rate of 1.5% (3.5%) for the bHPV compared with the
qHPV. In the scenarios explored, using a discount rate of 1.5%
makes bHPV the dominant choice over qHPV.Impact of time
The profiles of the two HPV vaccines differmarkedly -in terms
of what they are expected to prevent against and also at what
time point this protection is anticipated to occur.
CC can take many years to develop (median age of CC
diagnosis is 49 years peak age between 30 and 34, and 80 and
84),9 whilst prevention of GW can occur soon after vaccination
(peak from ages 16e24).10 Thus, total QALYs gained related to
CC are impacted relatively more by discounting than total
QALYs gained associated with GW (see Table 1 and
Supplementary Fig. 1).
Taking a snapshot, most of the total undiscounted GW
related QALYs gained is captured in the benefits part of the
cost-effectiveness evaluation: 80% (62%) is captured with a
1.5% (3.5%) discount rate compared with only 60% (24%) of the
total undiscounted CC related QALYs gained (Table 1).
Furthermore, 76% (59%) of the value of GW is captured within
30 years after vaccination, when the majority of cases occur,
whereas only 5% (3%) of the benefit of CC prevention is
captured after 30 years post vaccination, after which point
approximately 40% of CC cases are expected to occur9 when
using a discount rate of 1.5% (3.5%). This is also illustrated in
Supplementary Fig. 1.
Thus, using a 1.5% discount rate preserves more of the
benefit over time.Discussion
Both bHPV and qHPV have been reported to provide protection
against CC, CIN1 and CIN2/3 caused by HPV-16/18 as well as
cross-protection against non-vaccine HPV-types. However,
because the clinical profiles of these two vaccines differ
markedly especially in terms of protection against non-
vaccine types, this may translate into bHPV offering greater
protection against CC, CIN1, CIN2/3, with fewer associated
deaths, compared with qHPV (Table 1).The time at which events occur is likely to have a sub-
stantial impact on the assessment of cost-effectiveness. HPV
vaccination prevents outcomes at different time points,
resulting in vastly different contributions to the outcomes
side of the equation when discounting. The contribution of
benefits per outcome ranged from 76% to 3% depending on the
time at which the event would otherwise take place, and the
discount rate used.
These analyses demonstrate the importance of under-
standing this effect and taking steps to ensure that there is not
an inadvertent overvaluing of any one outcome over another.
Furthermore, by applying a discount rate of 1.5%, bHPVwas
found to dominate qHPV in all scenarios. Amodest decrease in
GW incidence in girls vaccinated with bHPV has been reported
in England,6 resulting in increased QALY benefit and reduced
cost for bHPV compared with qHPV.
The limitations of the study were primarily due to limita-
tions in the model being static, where the benefit of herd-
effect and protection offered to unvaccinated women
against HPV infection were not considered.
In conclusion, the applied discount rate is important when
evaluating benefits associated with HPV vaccination. Indeed,
policy makers may need to acknowledge the impact of the
discount rate used on cost-effectiveness calculations for
different vaccines and should select themost appropriate rate
based on the objectives of the specific vaccination
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